

CURRICULUM VITAE

1. PERSONAL INFORMATION

- **Name:** Heidar Sharafi
- **Date of Birth:** September 01, 1985
- **Place of Birth:** Tehran, Iran
- **Nationality:** Iranian
- **Phone no:** +98-9125176030
- **Email:** Heidarsharafi@gmail.com

2. PROFILES IN SOCIAL NETWORKS

- **LinkedIn:** <https://ir.linkedin.com/in/heidar-sharafi-35b6a438>
- **ResearchGate:** https://www.researchgate.net/profile/Heidar_Sharafi
- **Google Scholar:** <https://scholar.google.com/citations?user=pMBlhWgAAAAJ&hl=en>
- **Publons:** <https://publons.com/author/306970/heidar-sharafi>
- **Scopus:** <https://www.scopus.com/authid/detail.uri?authorId=54894153700>

3. EDUCATION

- **Doctorate of Philosophy (PhD)**
Baqiyatallah University of Medical Sciences; 2013-2019
- **Master of Science (MS), Hematology and Transfusion Medicine**
Tehran University of Medical Sciences; 2008-2011
- **Bachelor of Science (BS), Medical Laboratory Technology**
Iran University of Medical Sciences; 2006-2008

4. WORK EXPERIENCES & POSITIONS

- Secretary General. Iran Hepatitis Network; 2017-2019
- Research Assistant. Middle East Liver Disease Center; 2013-now
- Research Director. Iran Hepatitis Network; 2013-2017
- Supervisor of Molecular Diagnosis Section. Armin Pathobiology Laboratory; 2011-2016
- Molecular Laboratory Technologist. Gholhak Medical Laboratory; 2009-2011
- Clinical Laboratory Technologist. Payvand Medical Laboratory; 2007-2008

5. SELECTED PUBLICATIONS (Among 66 publications of author in Scopus-indexed journals)

1. **Sharafi H**, et al. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2018;392(10159):2091 - 138.

2. **Sharafi H**, et al. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2018;392(10159):1684 - 735.
3. **Sharafi H**, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2018;392(10159):1923-94.
4. Haghgoo SM, **Sharafi H**, Alavian SM. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. *Clin Chem Lab Med*. 2018. doi:10.1515/cclm-2018-0357.
5. **Sharafi H**, Maleki S, Alavian SM. Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. *Virus research*. 2019;259:54-61.
6. **Sharafi H**, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? *World J Hepatol*. 2018;10(9):543-8.
7. **Sharafi H**, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. *Hepat Mon*. 2017;17(6):e12216.
8. Alavian SM, **Sharafi H**. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. *Hepat Mon*. 2017;17(11):e63956.
9. **Sharafi H**, Karimi-Sari H, Alavian SM. The high-diagnostic characteristics of HBsAg level in differentiation of hepatitis B clinical presentations: Myth or truth? *Liver Int*. 2017;37(4):620-1.
10. Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, **Sharafi H**. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. *Ann Hepatol*. 2017;16(2):188-97.
11. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, **Sharafi H**, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. *Hepat Mon*. 2016;16(8):e40959.
12. Hesamizadeh K, **Sharafi H**, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps for Eradication of Hepatitis C in the Era of Direct Acting Antivirals. *Hepat Mon*. 2016;16(4):e37089.
13. Keshvari M, **Sharafi H**, Alavian SM, Mehrabadi H, Zolfaghari S. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. *Transfus Apher Sci*. 2015;53(1):38-47.
14. Sali S, **Sharafi H**, Alavian SH, Alavian SM, Etesam F, Salimi S, et al. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state? *Diagn Microbiol Infect Dis*. 2015;82(2):114-119.
15. **Sharafi H**, Alavian SM, Behnava B, Pouryasyn A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. *Hepat Mon*. 2014;14(10):e22649.
16. Keshvari M, Alavian SM, Aghaee B, Behnava B, Mahdavi M, Fesharaki MG, **Sharafi H**. Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization. *Transfus Med*. 2014;24(6):411-7.
17. **Sharafi H**, Pouryasyn A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. *Hepat Mon*. 2012;12(3):190-5.

6. SCIENTIFIC EDITOR & REVIEWER

- Associate editor and reviewer for the journal of *Hepatitis Monthly*.
- Science editor and reviewer for the journal of *Plos One*.
- Editorial board and Reviewer for the *World Journal of Hepatology*.
- Editorial board for the *European Medical Journal. Hepatology*.
- Reviewer for the *Journal of Clinical Virology*.
- Reviewer for the *Journal of Medical Virology*.
- Reviewer for the *World Journal of Gastroenterology*.
- Reviewer for the *Infection and Drug Resistance*.
- Reviewer for the *Viral Immunology*.
- Reviewer for the *Bulletin of the World Health Organization*.
- Reviewer for the *Liver International*.
- Reviewer for the *PeerJ*.
- *And 11 more.*

7. SKILLS

- Molecular diagnosis of viral hepatitis.
- Molecular techniques, DNA & RNA extraction, PCR & RT-PCR techniques, Agarose & PAGE electrophoresis.
- PCR primer design, DNA sequencing and phylogenetic analysis.
- Molecular Cloning.
- Computer skills: Microsoft Office PowerPoint & Microsoft Office Word Software.
- Statistical analysis.

8. AWARDS

- Publons top reviewer award (Medicine): 2017 and 2018.
- Early career research fellowship funded by APASL, 2017.
- Clinical Laboratory Technology (BS) top student of Iran University of Medical Sciences (IUMS) with GPA 19.37 out of 20.

9. REFERENCES

- Prof. Seyed Moayed Alavian, Director and founder of Middle East Liver Diseases Center
Email: alavian@thc.ir
Phone: +98 912 107 3195
Nature of relationship: Prof. Alavian has been my mentor for the previous 6 years
- Dr. Behzad Hajarizadeh, Senior Lecturer at The Kirby Institute, The University of New South Wales
Email: bhajarizadeh@kirby.unsw.edu.au
Phone: +61 406 851 000

Nature of relationship: Behzad has been the consultant of Iran Hepatitis Network and we have co-worked on few projects (IL28B, epidemiology of viral hepatitis and elimination of hepatitis C in Iran).

- Dr. Ali Mirzazadeh, Assistant Professor at University of California San Francisco

Email: Ali.Mirzazadeh@ucsf.edu

Phone: +1 415 866 4234

Nature of relationship: I know Ali for a year and we have closely worked a joint project named ROSTAM study for screening and treatment of HCV in people who inject drug.